Finnegan Remains a Tier 1 Firm in the 2024 LMG Life Sciences Rankings

FOR IMMEDIATE RELEASE
October 4, 2024

WASHINGTON, DC— Finnegan received Tier 1 rankings by LMG Life Sciences in all major IP categories, including General Patent Litigation, Hatch-Waxman Patent Litigation (Branded), Patent Prosecution, and Patent Strategy and Management. The LMG Life Sciences annual rankings highlight the most recommended groups from the United States and Canada for financial and corporate, intellectual property, litigation and enforcement, and regulatory matters. The rankings are a result of a rigorous, months long research process that includes firm participation in questionnaires, partner interviews, client surveys, as well as independent research. Finnegan is pleased to have received consecutive top tier placement since the inception of the LMG Life Sciences rankings in 2012.

Our life sciences practice includes attorneys and professionals with degrees in relevant scientific disciplines such as biology, chemistry, biochemistry, medicine, pharmacology, biomedical engineering, and electrical engineering. Our attorneys advise clients on virtually every intellectual property issue related to the complex and evolving area of biologics, including patent prosecution, due diligence investigations, portfolio management, and litigation. Finnegan’s life sciences practice also includes attorneys with extensive experience in brand management and protection. Since being involved in the very first Abbreviated New Drug Application (ANDA) litigation in the United States, Finnegan has been a leading firm representing innovative pharmaceutical companies before federal district courts and the U.S. Court of Appeals for the Federal Circuit. Our successes derive from a deep bench of experienced and technically sophisticated attorneys who understand the long-term plans of innovative pharmaceutical companies as well as the legal particularities of ANDA litigation under the Hatch-Waxman Act and the nuances of pharmaceutical patent law. 

Finnegan’s attorneys are also continuously recognized as leaders in the life sciences industry. This year, 13 Finnegan attorneys were recognized by LMG Life Sciences for their dynamic work in the sector:

Michele C. Bosch – General Patent Litigation, Patent Strategy & Management
L. Scott Burwell – General Patent Litigation, Hatch-Waxman Patent Litigation
Bryan C. Diner – Patent Strategy & Management, Hatch-Waxman Patent Litigation
Mark J. Feldstein, Ph.D. – General Patent Litigation, Hatch-Waxman Patent Litigation
Jeffrey M. Jacobstein – Patent Prosecution, Patent Strategy & Management
J. Michael Jakes – General Patent Litigation, Patent Strategy & Management
Charles E. Lipsey – General Patent Litigation, Hatch-Waxman Patent Litigation
John D. Livingstone – Hatch-Waxman Patent Litigation
Leslie A. McDonell – Patent Prosecution, Patent Strategy & Management
James B. Monroe – General Patent Litigation
William B. Raich, Ph.D. – General Patent Litigation
Jennifer H. Roscetti – General Patent Litigation
M. David Weingarten, Ph.D. – Patent Prosecution, Patent Strategy & Management

In addition to the rankings, LMG Life Science recently hosted its annual Americas Awards in New York City, where they honored life science practitioners and firms across the United States, Canada, and Brazil. Five partners took home awards and the firm was named Firm of the Year – Intellectual Property. For a complete list of award recipients, click here.

Contacts

Erika H. Arner, Managing Partner
erika.arner@finnegan.com

Anand K. Sharma, Chair
anand.sharma@finnegan.com

About Finnegan
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is one of the largest IP law firms in the world. From offices in Atlanta, Boston, London, Munich, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo, and Washington, DC, the firm practices European, German, UK, and U.S. IP law. In addition to services related to all aspects of patent, trademark, and copyright law, including counseling, prosecution, licensing, and litigation, Finnegan provides counseling and litigation services in advertising, privacy, and a wide spectrum of additional IP-adjacent commercial matters, including trade secrets, international trade, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com and follow us on LinkedIn.